Medicines for All Institute Develops New, Cost-Saving Synthesis of Anti-HIV Drug Emtricitabine

The Medicines for All Institute (M4ALL), which seeks to reduce the costs of manufacturing HIV/AIDS treatments and other lifesaving medications, has developed a new, efficient route to 5-fluorocytosine (5FC), a key starting material used in the synthesis of the anti-HIV drug emtricitabine.